dl-Tetramisol en es it fr

dl-Tetramisol Brand names, dl-Tetramisol Analogs

dl-Tetramisol Brand Names Mixture

  • No information avaliable

dl-Tetramisol Chemical_Formula


dl-Tetramisol RX_link


dl-Tetramisol fda sheet

dl-Tetramisol FDA

dl-Tetramisol msds (material safety sheet)

dl-Tetramisol MSDS

dl-Tetramisol Synthesis Reference

No information avaliable

dl-Tetramisol Molecular Weight

337.346 g/mol

dl-Tetramisol Melting Point

No information avaliable

dl-Tetramisol H2O Solubility

3 mg/mL

dl-Tetramisol State


dl-Tetramisol LogP


dl-Tetramisol Dosage Forms

Solution; Tablets

dl-Tetramisol Indication

For the treatment of bacterial infections caused by susceptible strains of vancomycin resistant Enterococcus faecium, Staphylococcal aureus (methicillin resistant and susceptible strains), Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae.

dl-Tetramisol Pharmacology

Linezolid is a synthetic antibacterial agent of a new class of antibiotics, the oxazolidinones, which has clinical utility in the treatment of infections caused by aerobic Gram-positive bacteria. The in vitro spectrum of activity of linezolid also includes certain Gram-negative bacteria and anaerobic bacteria. Susceptible organisms include methicillin- and vancomycin-resistant staphylococci, vancomycin-resistant enterococci, penicillin-resistant pneumococci and anaerobes. Oxazolidinones inhibit protein synthesis by binding at the P site at the ribosomal 50S subunit. Resistance to other protein synthesis inhibitors does not affect oxazolidinone activity, however rare development of oxazolidinone resistance cases, associated with 23S rRNA alterations during treatment have been reported. Linezolid inhibits bacterial protein synthesis through a mechanism of action different from that of other antibacterial agents; therefore, cross-resistance between linezolid and other classes of antibiotics is unlikely.

dl-Tetramisol Absorption

Linezolid is rapidly and extensively absorbed after oral dosing. Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.

dl-Tetramisol side effects and Toxicity

Clinical signs of acute toxicity lead to decreased activity, ataxia, vomiting and tremors.

dl-Tetramisol Patient Information

dl-Tetramisol Organisms Affected

Gram negative and gram positive bacteria